CTOs on the Move


 
Pieris Pharmaceuticals is a clinical stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.pieris.com
  • 255 State Street 9th floor
    Boston, MA USA 02109
  • Phone: 857.246.8998

Executives

Name Title Contact Details

Funding

Pieris raised $50.6M on 02/20/2018
Pieris raised $32M on 11/10/2019
Pieris raised $17.3M on 06/25/2021
Pieris raised $25M on 07/05/2021

Similar Companies

New Health Sciences

New Health Sciences is developing Hemanext, a technology designed to improve the safety and efficacy of transfusion therapy through novel storage methods.

Dainippon Sumitomo Pharma America Holdings

Dainippon Sumitomo Pharma America Holdings is a Fort Lee, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

IVX Health

Our local centers provide infusion care such as Remicade, Ocrevus, and Entyvio and injections like Xolair and Fasenra for patients with ongoing conditions.

The Alkalol Company

The Alkalol Company is a Boston, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Soliton

Soliton has developed breakthrough science for tattoo removal using Rapid Acoustic Pulse (RAP) technology, which when combined with existing laser technology can rapidly accelerate tattoo removal.